1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator's choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma.
Saved in:
| Title: | 1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator's choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma. |
|---|---|
| Authors: | Butler, M.O.1 (AUTHOR), Weight, R.2 (AUTHOR), Haq, R.3 (AUTHOR), Javed, A.4 (AUTHOR), Chandana, S.5 (AUTHOR), Chmielowski, B.6 (AUTHOR), Dummer, R.7 (AUTHOR), Carlino, M.S.8 (AUTHOR), Mckean, M.9 (AUTHOR), Moser, J.10 (AUTHOR), Chandrasekaran, S.11 (AUTHOR), Khan, S.12 (AUTHOR), Kim, K.B.13 (AUTHOR), Lutzky, J.14 (AUTHOR), Shackleton, M.15 (AUTHOR), Atkinson, V.G.16 (AUTHOR), Beaupre, D.17 (AUTHOR), Cole, G.W.18 (AUTHOR), Patel, H.19 (AUTHOR), Orloff, M.20 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS747-S747. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 179693472 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator's choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Butler%2C+M%2EO%2E%22">Butler, M.O.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Weight%2C+R%2E%22">Weight, R.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Haq%2C+R%2E%22">Haq, R.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Javed%2C+A%2E%22">Javed, A.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chandana%2C+S%2E%22">Chandana, S.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chmielowski%2C+B%2E%22">Chmielowski, B.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dummer%2C+R%2E%22">Dummer, R.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Carlino%2C+M%2ES%2E%22">Carlino, M.S.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mckean%2C+M%2E%22">Mckean, M.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Moser%2C+J%2E%22">Moser, J.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chandrasekaran%2C+S%2E%22">Chandrasekaran, S.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Khan%2C+S%2E%22">Khan, S.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kim%2C+K%2EB%2E%22">Kim, K.B.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lutzky%2C+J%2E%22">Lutzky, J.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shackleton%2C+M%2E%22">Shackleton, M.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Atkinson%2C+V%2EG%2E%22">Atkinson, V.G.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Beaupre%2C+D%2E%22">Beaupre, D.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cole%2C+G%2EW%2E%22">Cole, G.W.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Patel%2C+H%2E%22">Patel, H.</searchLink><relatesTo>19</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Orloff%2C+M%2E%22">Orloff, M.</searchLink><relatesTo>20</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2024 Supplement 2, Vol. 35, pS747-S747. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=179693472 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2024.08.2142 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S747 Titles: – TitleFull: 1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator's choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Butler, M.O. – PersonEntity: Name: NameFull: Weight, R. – PersonEntity: Name: NameFull: Haq, R. – PersonEntity: Name: NameFull: Javed, A. – PersonEntity: Name: NameFull: Chandana, S. – PersonEntity: Name: NameFull: Chmielowski, B. – PersonEntity: Name: NameFull: Dummer, R. – PersonEntity: Name: NameFull: Carlino, M.S. – PersonEntity: Name: NameFull: Mckean, M. – PersonEntity: Name: NameFull: Moser, J. – PersonEntity: Name: NameFull: Chandrasekaran, S. – PersonEntity: Name: NameFull: Khan, S. – PersonEntity: Name: NameFull: Kim, K.B. – PersonEntity: Name: NameFull: Lutzky, J. – PersonEntity: Name: NameFull: Shackleton, M. – PersonEntity: Name: NameFull: Atkinson, V.G. – PersonEntity: Name: NameFull: Beaupre, D. – PersonEntity: Name: NameFull: Cole, G.W. – PersonEntity: Name: NameFull: Patel, H. – PersonEntity: Name: NameFull: Orloff, M. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2024 Supplement 2 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 35 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
